WuXi AppTec Co., Ltd. (HKG:2359)

Market Cap	182.53B
Revenue (ttm)	42.45B
Net Income (ttm)	11.99B
Shares Out	n/a
EPS (ttm)	3.48
PE Ratio	15.23
Forward PE	13.86
Dividend	1.09 (1.73%)
Ex-Dividend Date	Jun 17, 2024

Volume	1,719,572
Average Volume	8,226,579
Open	61.15
Previous Close	62.80
Day's Range	62.45 - 63.80
52-Week Range	27.50 - 76.00
Beta	0.87
RSI	56.89
Earnings Date	Apr 28, 2025

About WuXi AppTec

WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs and advanced therapies in the People’s Republic of China, the United States, Europe, and internationally. The company operates in six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2000
• Employees: 39,414
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2359

Financial Performance

In 2024, WuXi AppTec's revenue was 37.92 billion, a decrease of -1.97% compared to the previous year's 38.68 billion. Earnings were 9.45 billion, a decrease of -1.63%.

Financial numbers in CNY